» Articles » PMID: 36628510

Icariin Has a Synergistic Effect on the Osteoinductivity of Bone Morphogenetic Protein 2 at Ectopic Sites

Overview
Journal Orthop Surg
Specialty Orthopedics
Date 2023 Jan 11
PMID 36628510
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Establishing biocompatible, biodegradable, osteoconductive, and osteoinductive bone materials remains a challenging subject in the research of bone healing and bone regeneration. Previously, we demonstrated the osteogenic and osteoconductive effects of biomimetic calcium phosphate (BioCaP) incorporating with Icariin and/or bone morphogenetic protein 2 (BMP-2) at orthotopic sites.

Methods: By implanting the BioCaP granules incorporated Icariin and/or BMP-2 into the dorsal subcutaneous pockets of adult male Sprague-Dawley (S-D) rats (6-7 weeks old), we investigated the osteoinductive efficacy of the samples. Micro-computed tomography(micro-CT) observations and histological slices were used to verify the osteoinduction of this system on the 2 and 5 week. Statistical significances was evaluated using Turkey's post hoc test of one-way analysis of variance.

Results: The osteoinduction of the BioCaP incorporated with BMP-2 or both agents was confirmed as expected. BioCaP with Icariin alone could not generate bone formation at an ectopic sites. Nevertheless, co-administration of Icariin increased bone mineral density (BMD; p < 0.01) (628mg HA/cm vs 570mg HA/cm ) and completely changed the distribution of newly formed bone when compared with the granules with BMP-2 alone, even though there was no significant difference in the volume of newly formed bone. In contrast, the BioCaP with both agents (37.86%) had significantly fewer remaining materials than the other groups by the end of the fifth week (53.22%, 53.62% and 48.22%) (p < 0.01).

Conclusion: The co-administration of Icariin and BMP-2 increased BMD changed the distribution of newly formed bone, and reduced the amount of remaining materials. Therefore, Icariin can stimulate BMP-2 when incorporated into BioCaP granules at ectopic sites, which makes it useful for bone tissue engineering.

References
1.
Wang J, Liu B, Zhang C, Wang X, Zhen D, Huang X . Effects of icariin on ovarian function in d-galactose-induced aging mice. Theriogenology. 2018; 125:157-167. DOI: 10.1016/j.theriogenology.2018.10.028. View

2.
Wang J, Zheng Y, Zhao J, Liu T, Gao L, Gu Z . Low-dose rhBMP2/7 heterodimer to reconstruct peri-implant bone defects: a micro-CT evaluation. J Clin Periodontol. 2011; 39(1):98-105. DOI: 10.1111/j.1600-051X.2011.01807.x. View

3.
Kawecki F, Clafshenkel W, Fortin M, Auger F, Fradette J . Biomimetic Tissue-Engineered Bone Substitutes for Maxillofacial and Craniofacial Repair: The Potential of Cell Sheet Technologies. Adv Healthc Mater. 2017; 7(6):e1700919. DOI: 10.1002/adhm.201700919. View

4.
Kim Y, Tabata Y . Dual-controlled release system of drugs for bone regeneration. Adv Drug Deliv Rev. 2015; 94:28-40. DOI: 10.1016/j.addr.2015.06.003. View

5.
Zhang X, Lin X, Liu T, Deng L, Huang Y, Liu Y . Osteogenic Enhancement Between Icariin and Bone Morphogenetic Protein 2: A Potential Osteogenic Compound for Bone Tissue Engineering. Front Pharmacol. 2019; 10:201. PMC: 6423068. DOI: 10.3389/fphar.2019.00201. View